Joel Greenblatt's Magic Formula flags Peabody Energy, Molina Healthcare, and H&R Block as cheap businesses worth owning, but cheap and high-quality still fails retirement investors if the income dries up when markets turn ugly.
BlackBerry, Nokia, and IBM have all surged back into the investor conversation, but three decades of fallen-titan history reveals a brutal filter that only one type of comeback ever passes.
Apple and Microsoft have both seen notable drawdowns, but the shape of each dip tells a completely different story about risk, growth, and where your retirement money belongs.
QQQM barely pays a dividend, so most investors assume the Roth math is trivial. They are missing the place where the real tax bill hides.
Three legendary hedge fund managers walked away from Alphabet, Delta, and Southwest Gas, yet all three stocks kept climbing after the exit. Whether that makes the billionaires look wrong or simply early is the…
Big pharma is hunting again, and patent cliffs are forcing buyers to overpay or miss out. Three mid-cap biotechs have quietly positioned themselves as prime acquisition targets, but only one offers the rare combination…
Netflix shares have shed nearly half their value over the past year, and management is betting on advertising, live events, and gaming to reignite growth. Whether those bets are paying off fast enough is…
SoFi and Ally reported Q1 results that could not look more different, and the gap between their strategies raises a pointed question for investors: does the smarter bet right now favor a product-stacking growth…
Billionaire investor Stanley Druckenmiller has filed positions in three AI infrastructure semiconductor stocks, but the real question is whether the valuations still make sense after one of them surged over 600% in a single…
Two company directors spent millions buying their own stock in the days after a brutal earnings miss, right near 52-week lows, while every analyst covering the name holds a price target far above where…
Big Pharma's patent cliffs are forcing acquirers to hunt for revenue-producing biotech assets before rivals snap them up, and three names keep surfacing in deal speculation. One already has a natural buyer embedded in…
Reddit traders are piling into Celsius, Chewy, and Estée Lauder with serious conviction, but Wall Street is only nodding along on two of them. Find out which stock has retail and analysts sharply at…
Gold sitting in a taxable brokerage account creates a tax problem most investors miss until the sale settles. Here's what to do.
Two stocks chased the same Bitcoin boom from opposite angles, and a decade later their returns tell a story that might surprise anyone who assumed mining the coin beats holding it.
Stanley Druckenmiller’s Duquesne Family Office disclosed positions in Arm Holdings (NASDAQ: ARM | ARM Price Prediction), Sea Limited (NYSE: SE), and STMicroelectronics (NYSE: STM) in its Q1 2026 13F, filed May 15, 2026. According…
Big pharma’s appetite for clinical-stage biotech is back. The pending acquisition of Apogee Therapeutics by AbbVie (NYSE: ABBV | ABBV Price Prediction), targeting an atopic dermatitis and immunology developer, has reignited a question every…
Two major industrial restructurings are about to reshape share counts at DuPont de Nemours (NYSE: DD | DD Price Prediction) and Honeywell (NASDAQ: HON). Both companies have confirmed reverse stock splits tied to portfolio…
From Sleepy Chip Shops to AI Infrastructure Pillars Ten years ago, Marvell Technology (NASDAQ: MRVL | MRVL Price Prediction) was a fabless chipmaker leaning on declining hard-drive controllers. Micron Technology (NASDAQ: MU) was a…
At the 24% bracket, a high-yield dividend portfolio bleeds thousands to the IRS every year. A passive S&P 500 position behaves differently. The Vanguard S&P 500 ETF (NYSEARCA: VOO) yields roughly 1.2%, and its…
Cult stocks attract acquisition speculation the way magnets attract iron filings. A loyal retail base, a strategic asset, and a richly debated future are exactly the ingredients buyers and analysts love to game out.…
